person · Reporting owner
Smith Devin Whittemore
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | General Counsel | April 02, 2025 | April 04, 2025 |
| KINETA, INC./DEYMTX · Entity 77778 | SVP and General Counsel | December 02, 2022 | December 06, 2022 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | SVP and General Counsel | October 13, 2020 | October 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date April 02, 2025 · Filed April 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-04-02 | Direct | 140,000 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 140,000 · Balance 140,000 F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.
KINETA, INC./DE
Report date December 02, 2022 · Filed December 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,961 |
Reported balance
After 2022-12-02 transaction · row 1
1 source rowRow 1 · 2022-12-02 · Sale · Disposed 3,116 · Balance 13,961 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Minerva Neurosciences, Inc.
Report date October 13, 2020 · Filed October 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2030-10-12 | Direct | 85,000 |
Reported balance
After 2020-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-13 · Grant · Acquired 85,000 · Balance 85,000 F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2025 Filed Apr 4, 2025 20:13 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000905148-25-001094 · form4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-04-02 F1 · derivative.exercise_date: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 23:52 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 12,000 | $0.81 | $9,720.00 |
DisclosureSEC source: 0000905148-24-003408 · form4.xml · nonDerivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,938 Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:23 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000905148-24-000968 · form4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 00:38 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantWarrants (Right to Buy) · Derivative | 4,938 | $0.13 Strike: $2.47 | $617.25 |
DisclosureSEC source: 0001140361-23-038877 · form4.xml · derivative · entry 2 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,938 Underlying: Common Stock · 4,938 shares Expires not disclosed F1 · derivative.expiration_date: These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 00:38 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantCommon Stock | 4,938 | $1.90 | $9,382.20 |
DisclosureSEC source: 0001140361-23-038877 · form4.xml · nonDerivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,938 Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:49 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001567619-23-000919 · doc1.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-12 F1 · derivative.exercise_date: One-fourth of these options vest on January 12, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 16:51 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 3,116 | $1.69 | $5,269.16 |
DisclosureSEC source: 0000899243-22-037785 · doc4.xml · nonDerivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,961 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:46 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 2,923 | $1.19 | $3,491.82 |
DisclosureSEC source: 0000899243-22-021285 · doc4.xml · nonDerivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.14 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:15 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046761 · doc4.xml · nonDerivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Restricted stock award granted under the Yumanity Therapeutics, Inc. Amended and Restated 2018 Stock Option and Grant Plan. Fifty percent of the shares subject to the award will vest six months after the grant date and fifty percent will vest twelve months after the grant date, provided that the award recipient continues to have a service relationship with the Company at such time. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 17:14 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 58,400 | $0.00 Strike: $16.20 | $0.00 |
DisclosureSEC source: 0000899243-21-024171 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,400 Underlying: Common Stock · 58,400 shares Expires 2031-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on June 14, 2022. The remaining 75% vest in equal monthly installments over the subsequent three years. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 17:23 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-20-054807 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-10-12 F1 · derivative.exercise_date: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022. Read SEC document |
| June 19, 2020 Filed Aug 17, 2020 16:32 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 153,531 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001209191-20-046957 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,531 Underlying: Common Stock · 153,531 shares Expires 2029-12-31 F1 · derivative.exercise_date: This option was granted by Issuer's Board of Directors on December 31, 2019 contingent upon stockholder approval of an amendment and restatement of Issuer's equity incentive plan to increase the number of shares available for issuance under such plan, which was received on June 19, 2020. This option vests 25% on December 31, 2020 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:53 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 41,469 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001209191-20-001129 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,469 Underlying: Common Stock · 41,469 shares Expires 2029-12-30 F1 · derivative.exercise_date: This option vests 25% on December 31, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:45 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001209191-18-062467 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests 25% on December 11, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:57 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (Righ to Buy) · Derivative | 200,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-18-045007 · doc4.xml · derivative · entry 1 Smith Devin Whittemore · CIK 0001747818 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-08-01 F1 · derivative.exercise_date: This option vests as to 25% of the shares on July 23, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.